Table 3.
Cumulative percentage in patients with drug-susceptible tuberculosis with culture negative overnight sputum samples and the median time to sputum culture conversion in the efficacy analysis population
| BloadPaZ group (n=57) | B200PaZ group (n=56) | HRZE group (n=59) | ||
|---|---|---|---|---|
| Percentage culture negative at day 56 of treatment (95% CI) | ||||
| Liquid culture | 67·4% (53·8–80·9) | 76·1% (64·0–88·3)* | 51·0% (36·6–65·4) | |
| Solid culture | 88·9% (79·8–97·9) | 84·0% (73·9–94·1) | 85·5% (75·7–95·3) | |
| Liquid culture median (IQR) time to culture negative, days | 49*(35 to not obtained) | 49* (35–56) | 56 (49 to not obtained) | |
BloadPaZ=bedaquiline (loading dose), pretomanid, and pyrazinamide. B200PaZ=bedaquiline (daily dose), pretomanid, and pyrazinamide. HRZE=isoniazid, rifampicin, pyrazinamide, and ethambutol.
*
Significantly different to the HRZE control; the median times were compared with the HRZE control using the log-rank test.